[go: up one dir, main page]

SG10201900536TA - Piperidine derivatives as orexin receptor antagonist - Google Patents

Piperidine derivatives as orexin receptor antagonist

Info

Publication number
SG10201900536TA
SG10201900536TA SG10201900536TA SG10201900536TA SG10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA
Authority
SG
Singapore
Prior art keywords
piperidine derivatives
orexin receptor
receptor antagonist
hypersomnia
obsessive
Prior art date
Application number
SG10201900536TA
Inventor
Haiying He
Songliang Wu
Yang Zhang
Biao Ma
Yuan Chen
Yuhe Wang
Shuhui Chen
Qiang Lv
Jiong Lan
Xing Liu
Original Assignee
Shanghai Haiyan Pharmaceutical Tech Co Ltd
Yangtze River Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54054589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201900536T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Haiyan Pharmaceutical Tech Co Ltd, Yangtze River Pharmaceutical Group Co Ltd filed Critical Shanghai Haiyan Pharmaceutical Tech Co Ltd
Publication of SG10201900536TA publication Critical patent/SG10201900536TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONIST The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, hypersomnia, anxiety, obsessive-compulsive disorder, panic attack, nicotine addiction, or binge eating disorder. 10 (No suitable figure)
SG10201900536TA 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist SG10201900536TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410081220 2014-03-06

Publications (1)

Publication Number Publication Date
SG10201900536TA true SG10201900536TA (en) 2019-02-27

Family

ID=54054589

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900536TA SG10201900536TA (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist
SG11201607183PA SG11201607183PA (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201607183PA SG11201607183PA (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist

Country Status (16)

Country Link
US (1) US10100047B2 (en)
EP (1) EP3115362B1 (en)
JP (1) JP6262885B2 (en)
KR (1) KR101920472B1 (en)
CN (1) CN106414439B (en)
AU (1) AU2015226679B2 (en)
CA (1) CA2941663C (en)
CL (1) CL2016002240A1 (en)
IL (1) IL247584A0 (en)
MX (1) MX2016011549A (en)
NZ (1) NZ723671A (en)
PE (1) PE20170184A1 (en)
RU (1) RU2669701C2 (en)
SG (2) SG10201900536TA (en)
WO (1) WO2015131773A1 (en)
ZA (1) ZA201606141B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161035A1 (en) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
CN106349228B (en) 2015-07-17 2019-07-09 广东东阳光药业有限公司 Substituted quinazolinone compounds and preparation method and use thereof
CN107709318B (en) 2015-08-14 2020-09-25 上海海雁医药科技有限公司 Preparation method of orexin receptor antagonist receptor compound and its intermediate and crystal form
CA3005918C (en) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
US10508083B2 (en) 2016-02-04 2019-12-17 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
JP7478839B2 (en) * 2020-04-17 2024-05-07 上海海雁醫藥科技有限公司 Solid pharmaceutical formulations, and methods for their manufacture and use
CN112480107B (en) * 2020-11-30 2022-08-16 上海海雁医药科技有限公司 Substituted azabicyclooctane compounds, intermediates therefor and processes for their preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501859A (en) * 2003-05-13 2007-02-01 シェーリング　コーポレイション Bridged n-arylsulfonylpiperidines as γ-secretase inhibitors
US20090247499A1 (en) * 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
JP2010527924A (en) * 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション Oxo-bridged diazepan orexin receptor antagonist
ES2379744T3 (en) * 2007-05-23 2012-05-03 Merck Sharp & Dohme Corp. Pyridyl-piperidine antagonists of orexin receptors
US8030495B2 (en) * 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
ES2528129T3 (en) * 2008-02-06 2015-02-04 Msd K.K. Sulfonyl piperazine derivative substituted at position 3
EP2247586B1 (en) * 2008-02-21 2012-04-25 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
US8357700B2 (en) * 2008-10-21 2013-01-22 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
WO2010048014A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
EP2350066B1 (en) * 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2563780B1 (en) * 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
AU2011283684B2 (en) * 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
EP2730573A4 (en) * 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINE DERIVATIVE
AR088352A1 (en) * 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
EP2752410B1 (en) * 2011-10-25 2016-08-31 Shionogi & Co., Ltd. Heterocycle derivative having pgd2 receptor antagonist activity
JOP20130213B1 (en) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co Oppositions to the 5-HT3 Future
CN104918939B (en) * 2012-11-16 2018-08-28 默沙东公司 Purine inhibitor of human phosphatidylinositol 3-kinase delta
TWI621618B (en) * 2013-03-13 2018-04-21 比利時商健生藥品公司 Substituted 2-azabicyclics and their use as orexin receptor modulators
TW201444849A (en) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
NZ723671A (en) 2017-05-26
CA2941663A1 (en) 2015-09-11
JP2017507185A (en) 2017-03-16
IL247584A0 (en) 2016-11-30
RU2016130937A (en) 2018-04-09
CN106414439A (en) 2017-02-15
PE20170184A1 (en) 2017-04-07
ZA201606141B (en) 2017-05-31
MX2016011549A (en) 2017-05-08
AU2015226679A1 (en) 2016-09-15
US10100047B2 (en) 2018-10-16
JP6262885B2 (en) 2018-01-17
WO2015131773A1 (en) 2015-09-11
AU2015226679B2 (en) 2017-05-25
KR20160143668A (en) 2016-12-14
RU2669701C2 (en) 2018-10-15
CA2941663C (en) 2020-02-18
SG11201607183PA (en) 2016-10-28
KR101920472B1 (en) 2019-02-08
CN106414439B (en) 2017-12-08
US20170233385A1 (en) 2017-08-17
EP3115362B1 (en) 2019-06-12
EP3115362A1 (en) 2017-01-11
CL2016002240A1 (en) 2017-02-17
EP3115362A4 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
SG10201900536TA (en) Piperidine derivatives as orexin receptor antagonist
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MA32975B1 (en) ANTAGONISTS OF C5AR
PH12019500131A1 (en) Substituted diazahetero-bicyclic compounds and their use
IL266302B (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
IL268928A (en) Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone and their use
WO2014120936A3 (en) Treatments for depression and other diseases with a low dose agent
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
CN110799501A (en) Crystal form of orexin receptor antagonist and preparation method and use thereof
DK2413933T4 (en) 2,4,6-Trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl] -benzamide for the treatment of migraine by oral or intravenous administration
CL2014003607A1 (en) Compounds derived from benzodioxol, acetylcholinesterase inhibitors; Preparation method; intermediary compounds; pharmaceutical composition; and use in the prevention or treatment of Alzheimer&#39;s disease.
MX371102B (en) New benzimidazole derivatives as antihistamine agents.
MD20140122A2 (en) Methods for producing anamorelin hydrochloride having a controlled chloride content
TN2014000532A1 (en) N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
PH12017501736B1 (en) Indole derivatives
MX2017017155A (en) Thromboxane receptor antagonists in aerd/asthma.
ZA201708762B (en) Crystalline form of fused pyridine derivative&#39;s maleate and uses thereof
PL407367A1 (en) Fried garlic and method for producing fried garlic
CN302567684S (en) Upper rail for hanging door
CN302457116S (en) storefront
HK1231767A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist